Diabetic Nephropathy

Intensive Urate-Lowering May Protect Kidneys in Type 2 Diabetes

Publish Date January 21, 2021

The effects of combined verinurad and febuxostat treatment were independent of blood pressure.

Albuminuria Down in Adults With Newly Diagnosed T2DM

Publish Date January 20, 2021

Improvements seen in glycemic, blood pressure, lipid control within the population partly explain decrease in albuminuria

Finerenone Gets Priority Review for Diabetic Kidney Disease

Publish Date January 18, 2021

The FDA has accepted for Priority Review the NDA for finerenone for chronic kidney disease in patients with type 2 diabetes.

Canagliflozin Beneficial Even for Advanced Kidney Disease

Publish Date December 9, 2020

Canagliflozin slows progression of kidney disease in participants with eGFR <30 mL/min/1.73 m² with no increase in AKI

Sotagliflozin Reduces Risk for Adverse CV Events in Diabetic Kidney Disease

Publish Date November 18, 2020

Sotagliflozin might help patients with diabetes and chronic kidney disease who are hospitalized with heart failure avoid a readmission, study results suggest.

Nephropathy Progression in Type 1 Diabetes Linked to Depression

Publish Date November 18, 2020

Whether successful treatment of depression reduces the risk for progression needs to be determined.

Finerenone NDA Submitted for Diabetic Kidney Disease

Publish Date November 11, 2020

The NDA for finerenone is supported by data from the double-blind, placebo-controlled phase 3 FIDELIO-DKD trial.

Highlights From the New KDIGO Guideline on Diabetes and CKD

Publish Date November 11, 2020

The new KDIGO guideline highlights specific management differences by CKD severity.

Patients With Diabetes and CVD on Empagliflozin Have Fewer CV, Renal Events

Publish Date November 5, 2020

Researchers assessed the risk for obstructive sleep apnea (OSA) among patients with type 2 diabetes and cardiovascular disease taking empagliflozin and further examined the effect of OSA on metabolic, cardiovascular, and renal outcomes.

Efficacy of Endothelin Receptor Antagonists for Renal Protection in Diabetic Kidney Disease

Publish Date November 4, 2020

Atrasentan outperformed both avosentan and bosentan for renoprotection in patients with type 2 diabetic kidney disease.